Cybin: Psychedelic Therapies to Treat Mental Illness

Using psychedelic molecules to address mental health disorders

Cybin Inc.’s primary focus is to take classical psychedelic molecules and transform them into useful therapeutic agents for mental health disorders. “We have a global issue and inadequate treatments. And that’s the problem we’re trying to solve,” says, CEO Doug Drysdale

One in four people will be affected by mental illness at some point in their lives. Further, those caring for someone with mental illness will experience anxiety or depression at a higher rate.

Cybin’s ambition is to improve the lives of those suffering from mental illness by changing the expectation of treatment. Today’s treatment options focus on managing symptoms, versus healing the underlying condition. Moreover, they often come with unpleasant side effects and low rates of success.

According to, Chief R&D Officer, Michael Palfreyman, there are two very important differences between a psychedelic and a classical pharmaceutical. One is that psychedelics work much more quickly. And the other is that you don’t have to give them every day to get a treatment response.

More on psychedelic therapies

Psychedelic therapies offer a novel approach to mental healthcare, focused on treating the underlying conditions as well as improving the patient experience and outcome. A paradigm shift in public policy has opened the door to new research and development in the field of psychedelic medicine and treatment regimens. “Now we have an ability to really address the underlying causes of depression, anxiety and addiction,” says Drysdale.

Cybin is at the forefront of this revolution. They believe that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape. While psychedelics may represent a new industry, the company recognizes the long history of use within indigenous cultures and major scientific breakthroughs over the decades that have led them to where we are today.

“I would predict, within five years we’re going to see psychedelic drugs approved for treating a number of serious mental illness problems,” says Palfreyman.

For more information on Cybin Inc. (NEO: CYBN, OTCQB: CLXPF) please click the request investor info button.